These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 18055666

  • 1. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 2. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
    Leibson CL, Barbaresi WJ, Ransom J, Colligan RC, Kemner J, Weaver AL, Katusic SK.
    Ambul Pediatr; 2006 Dec; 6(1):45-53. PubMed ID: 16443183
    [Abstract] [Full Text] [Related]

  • 3. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 4. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC, Wan GJ, Kemner JE, Olfson M.
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [Abstract] [Full Text] [Related]

  • 5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 6. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL, Kuchibhatla A.
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [Abstract] [Full Text] [Related]

  • 7. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N.
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [Abstract] [Full Text] [Related]

  • 8. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 9. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN, Lesesne CA, Perou R.
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [Abstract] [Full Text] [Related]

  • 10. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
    Varley CK, Vincent J, Varley P, Calderon R.
    Compr Psychiatry; 2001 Feb; 42(3):228-33. PubMed ID: 11349243
    [Abstract] [Full Text] [Related]

  • 11. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [Abstract] [Full Text] [Related]

  • 12. Injury among stimulant-treated youth with ADHD.
    Marcus SC, Wan GJ, Zhang HF, Olfson M.
    J Atten Disord; 2008 Jul; 12(1):64-9. PubMed ID: 17934179
    [Abstract] [Full Text] [Related]

  • 13. Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.
    Levin H, Hanten G, Max J, Li X, Swank P, Ewing-Cobbs L, Dennis M, Menefee DS, Schachar R.
    J Dev Behav Pediatr; 2007 Apr; 28(2):108-18. PubMed ID: 17435461
    [Abstract] [Full Text] [Related]

  • 14. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
    Winterstein AG, Gerhard T, Shuster J, Saidi A.
    Pediatrics; 2009 Jul; 124(1):e75-80. PubMed ID: 19564272
    [Abstract] [Full Text] [Related]

  • 15. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.
    Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ.
    J Dev Behav Pediatr; 2007 Aug; 28(4):274-87. PubMed ID: 17700079
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J, Wong KK, O'Connell C, Warren AE.
    Pediatrics; 2008 Oct; 122(4):e828-34. PubMed ID: 18829780
    [Abstract] [Full Text] [Related]

  • 17. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [Abstract] [Full Text] [Related]

  • 18. Pharmacotherapy with atomoxetine for US children and adolescents.
    Bhatara VS, Aparasu RR.
    Ann Clin Psychiatry; 2007 Aug; 19(3):175-80. PubMed ID: 17729019
    [Abstract] [Full Text] [Related]

  • 19. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC, Khoza S, Oladapo A.
    Curr Med Res Opin; 2011 Aug; 27 Suppl 2():13-22. PubMed ID: 21973228
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A.
    Expert Rev Neurother; 2006 Apr; 6(4):551-61. PubMed ID: 16623654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.